Cleerly ISCHEMIA vs FFRct

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Cleerly
VS
by HeartFlow

AI Verdict

Both Cleerly ISCHEMIA and HeartFlow FFRct are FDA-cleared AI tools that analyze CCTA scans to non-invasively assess coronary artery disease and ischemia, including FFR estimation. Cleerly ISCHEMIA provides vessel-level ischemia likelihood and comprehensive plaque characterization, while HeartFlow FFRct specifically leverages computational fluid dynamics to analyze blood flow and provide FFRct values. They are direct competitors for physicians seeking advanced non-invasive diagnostic insights from CCTA data.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if your clinical focus requires a detailed, vessel-level assessment of ischemia likelihood combined with comprehensive coronary plaque characterization (volume, type, and location). This tool is ideal for physicians seeking a deeper understanding of both the functional likelihood of ischemia and the underlying plaque morphology to inform personalized diagnosis and treatment strategies.

View Cleerly ISCHEMIA →

Choose FFRct if…

Choose FFRct if your primary goal is to non-invasively determine the functional significance of coronary artery stenoses by precisely quantifying blood flow (FFRct values) using computational fluid dynamics. This tool is particularly well-suited for guiding revascularization decisions, providing a clear physiological assessment to determine the necessity of intervention.

View FFRct →

When choosing between Cleerly ISCHEMIA and HeartFlow FFRct Analysis, physicians should consider their primary diagnostic focus and workflow preferences. Both tools leverage AI and CCTA scans to assess coronary artery disease non-invasively, but they offer distinct strengths. Cleerly ISCHEMIA excels at providing a comprehensive, vessel-level assessment of ischemia likelihood, coupled with detailed coronary plaque characterization and stenosis severity. It generates interactive web-based reports and 3D models, making it suitable for physicians who prioritize a detailed understanding of both plaque morphology and its potential functional impact.

HeartFlow FFRct Analysis, on the other hand, specializes in creating personalized 3D models to analyze blood flow and provide specific FFRct values, directly addressing the physiological significance of coronary narrowings. This tool is particularly beneficial for physicians who need a clear, quantitative assessment of blood flow to guide revascularization decisions. The key practical difference lies in their output: Cleerly ISCHEMIA offers a broader view of plaque and ischemia likelihood, while HeartFlow FFRct provides a direct, computational fluid dynamics-based assessment of blood flow restriction.

Therefore, a physician primarily focused on understanding the extent and characteristics of coronary plaque alongside ischemia risk might lean towards Cleerly ISCHEMIA. Conversely, a physician whose priority is a precise, non-invasive physiological assessment of blood flow to inform interventional strategies would likely find HeartFlow FFRct Analysis more aligned with their needs.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cleerly ISCHEMIA FFRct
Pricing Contact for details Contact for pricing
Deployment Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) Cloud-based (HeartFlow Network, AWS Cloud or Virtual Private Cloud), with a local Virtual Appliance for data transfer.
FDA Status 1 AI-estimated 1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both Cleerly ISCHEMIA and HeartFlow FFRct offer interactive web-based platforms for viewing results, including 3D models of coronary arteries. Cleerly highlights integration with PowerScribe, while HeartFlow mentions integration with PACS and HL7, indicating both prioritize seamless workflow integration and user experience.

Clinical Value

FFRct

While Cleerly ISCHEMIA demonstrates strong diagnostic accuracy and prognostic utility, particularly in plaque characterization and ischemia detection, HeartFlow FFRct has a more extensive body of evidence from large-scale, real-world studies (e.g., FISH&CHIPS with over 90,000 patients) demonstrating significant reductions in cardiovascular mortality and unnecessary invasive procedures. This broad, long-term impact on patient outcomes and healthcare efficiency gives HeartFlow an edge in overall clinical value.

Pricing & Value

FFRct

HeartFlow FFRct offers greater transparency with a published CMS payment rate of $1,017 (2025) and claims broad payer coverage (99%), indicating established reimbursement pathways. Furthermore, studies have demonstrated its cost-effectiveness by reducing unnecessary invasive procedures and generating healthcare savings.

Enterprise Readiness

FFRct

Both tools meet essential regulatory and security requirements (FDA clearance, HIPAA compliance, BAA). However, HeartFlow FFRct demonstrates a more extensive track record of enterprise adoption, having been implemented in over 1,400 institutions globally, and offers broader integration capabilities with PACS and HL7.

Innovation

Cleerly ISCHEMIA

While HeartFlow pioneered FFRct using computational fluid dynamics, Cleerly ISCHEMIA offers a distinct innovation by providing a comprehensive '3-in-1 approach' to assess atherosclerosis, stenosis, and ischemia, with detailed coronary plaque characterization (volume, type, and location). This focus on plaque morphology, in addition to functional assessment, provides a more holistic and potentially prognostic view of coronary artery disease.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer sufficient detail to differentiate between the two tools regarding the quality, breadth, or accessibility of their customer support and documentation. Both companies appear to offer various resources, but specific comparative metrics are lacking.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cleerly ISCHEMIA FFRct
Tool Name Cleerly ISCHEMIA FFRct
Company Cleerly HeartFlow
Core Analysis Method AI-enabled CCTA analysis; non-invasive fractional flow reserve (FFR) estimation; vessel-level ischemia likelihood determination AI and computational fluid dynamics (CFD); analyzes blood flow and identifies areas of narrowing (FFRct values)
Primary Output/Key Insight Vessel-level ischemia likelihood; coronary plaque characterization (volume, type, location); stenosis severity assessment; 3D digital models of coronary arteries; comprehensive interactive web-based reports Personalized 3D digital models of coronary arteries; blood flow analysis; FFRct values; aids in diagnosing coronary artery disease (CAD); helps guide treatment strategies and revascularization decisions
Integration Integration with PowerScribe via API Not specified

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and FFRct.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cleerly ISCHEMIA analyzes CCTA scans to determine the likelihood of coronary artery ischemia at a vessel level, offering non-invasive fractional flow reserve (FFR) estimation and comprehensive coronary plaque characterization. HeartFlow FFRct Analysis creates personalized 3D models from CCTA scans to assess blood flow and identify areas of narrowing using FFRct values, aiding in diagnosing coronary artery disease and guiding treatment strategies.
Cleerly ISCHEMIA uses AI-enabled CCTA analysis to assess atherosclerosis, stenosis, and the likelihood of ischemia, incorporating 37 measures of heart health. HeartFlow FFRct Analysis combines AI with computational fluid dynamics (CFD) to simulate blood flow through personalized 3D models of coronary arteries.
Cleerly ISCHEMIA provides detailed coronary plaque characterization, including volume, type, and location, along with stenosis severity assessment and comprehensive interactive web-based reports. HeartFlow FFRct Analysis focuses on analyzing blood flow to identify areas of narrowing (FFRct values) and helps guide treatment strategies and revascularization decisions.
Cleerly ISCHEMIA offers integration with PowerScribe via an API and provides comprehensive interactive web-based reports. HeartFlow FFRct Analysis is cloud-based and processes CCTA data to generate personalized 3D models and reports, aiding in diagnosis and treatment guidance.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.